(Q35542198)

8 August 2017

title

Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections (English)

1 reference

8 August 2017

Lode H

1

1 reference

8 August 2017

Wiley R

2

1 reference

8 August 2017

Höffken G

3

1 reference

8 August 2017

Wagner J

4

1 reference

8 August 2017

Borner K

5

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 October 1987

1 reference

Antimicrobial Agents and Chemotherapy

8 August 2017

published in

1 reference

8 August 2017

volume

31

1 reference

8 August 2017

issue

10

1 reference

8 August 2017

page(s)

1491-1496

1 reference

Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Pharmacokinetics of intravenously administered ciprofloxacin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Antibiotic susceptibility testing by a standardized single disk method

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Antimicrobial activity, bacterial resistance, and antimicrobial pharmacology. Is it possible to use new agents cost-effectively?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Imipenem: first of a new class of beta-lactam antibiotics

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Overview of clinical experience with ciprofloxacin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Ciprofloxacin in the treatment of pneumonia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174977

N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics

26 September 2018

1 reference

12 December 2020

In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid

1 reference

12 December 2020

Multiple dose pharmacokinetics and therapeutic results with ceftazidime

1 reference

12 December 2020

Imipenem therapy of Pseudomonas aeruginosa bacteraemia in neutropenic rats

1 reference

12 December 2020

A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam

1 reference

12 December 2020

Comparison of intravenous ciprofloxacin and mezlocillin in treatment of complicated urinary tract infection

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.31.10.1491

1 reference

8 August 2017

1 reference

8 August 2017

1 reference